JPWO2020089473A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020089473A5 JPWO2020089473A5 JP2021523958A JP2021523958A JPWO2020089473A5 JP WO2020089473 A5 JPWO2020089473 A5 JP WO2020089473A5 JP 2021523958 A JP2021523958 A JP 2021523958A JP 2021523958 A JP2021523958 A JP 2021523958A JP WO2020089473 A5 JPWO2020089473 A5 JP WO2020089473A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- nucleotide sequence
- plasmid
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 71
- 108090001123 antibodies Proteins 0.000 claims 71
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 30
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 20
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 20
- 241000700605 Viruses Species 0.000 claims 17
- 210000004027 cells Anatomy 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100003105 TNFRSF1B Human genes 0.000 claims 10
- 101710038524 TNFRSF1B Proteins 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 230000027455 binding Effects 0.000 claims 6
- 210000001519 tissues Anatomy 0.000 claims 5
- 230000001684 chronic Effects 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000035693 Fab Effects 0.000 claims 3
- 102000004851 Immunoglobulin G Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 210000000066 Myeloid Cells Anatomy 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001270 agonistic Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203996 | 2018-11-01 | ||
| EP18203996.6 | 2018-11-01 | ||
| PCT/EP2019/080003 WO2020089473A2 (en) | 2018-11-01 | 2019-11-01 | Novel agonistic antibody molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514179A JP2022514179A (ja) | 2022-02-10 |
| JPWO2020089473A5 true JPWO2020089473A5 (he) | 2022-10-26 |
Family
ID=64109795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523958A Pending JP2022514179A (ja) | 2018-11-01 | 2019-11-01 | 新規アゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220002426A1 (he) |
| EP (1) | EP3873935A2 (he) |
| JP (1) | JP2022514179A (he) |
| KR (1) | KR20210087466A (he) |
| CN (1) | CN112996812A (he) |
| AU (1) | AU2019370999A1 (he) |
| BR (1) | BR112021008007A2 (he) |
| CA (1) | CA3117756A1 (he) |
| IL (1) | IL282713A (he) |
| MX (1) | MX2021005151A (he) |
| WO (1) | WO2020089473A2 (he) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193196A1 (en) * | 2019-05-28 | 2022-06-23 | The Walter And Eliza Hall Institute Of Medical Research | Methods for Modulating T Cell Activation |
| JP2023529010A (ja) | 2020-06-12 | 2023-07-06 | ナンチン リーズ バイオラブス カンパニー，リミティド | Ｔｎｆｒ２に結合する抗体およびその用途 |
| EP4067381A1 (en) * | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| WO2022267926A1 (zh) * | 2021-06-22 | 2022-12-29 | 盛禾(中国)生物制药有限公司 | 一种抗tnfr2抗体及其制备方法和应用 |
| CN115925929A (zh) | 2021-09-22 | 2023-04-07 | 上海康岱生物医药技术股份有限公司 | 抗tnfr2单克隆抗体及其应用 |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| WO2023228082A1 (en) * | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anti-tnfr2 antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP3936137A1 (en) * | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| WO2016187068A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| US10988543B2 (en) * | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
| CN116715767A (zh) * | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
-
2019
- 2019-11-01 CA CA3117756A patent/CA3117756A1/en active Pending
- 2019-11-01 MX MX2021005151A patent/MX2021005151A/es unknown
- 2019-11-01 US US17/290,340 patent/US20220002426A1/en active Pending
- 2019-11-01 EP EP19805900.8A patent/EP3873935A2/en active Pending
- 2019-11-01 CN CN201980072437.7A patent/CN112996812A/zh active Pending
- 2019-11-01 KR KR1020217014401A patent/KR20210087466A/ko active Search and Examination
- 2019-11-01 AU AU2019370999A patent/AU2019370999A1/en active Pending
- 2019-11-01 JP JP2021523958A patent/JP2022514179A/ja active Pending
- 2019-11-01 BR BR112021008007-4A patent/BR112021008007A2/pt unknown
- 2019-11-01 WO PCT/EP2019/080003 patent/WO2020089473A2/en unknown
-
2021
- 2021-04-27 IL IL282713A patent/IL282713A/he unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| US9655964B2 (en) | Bispecific antibodies directed against TNF-α and IL-17 | |
| JP5918275B2 (ja) | 変形性関節症及び疼痛の治療 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| JP2013507929A (ja) | Ｉｌ−１結合蛋白質 | |
| JP2008502366A5 (he) | ||
| KR20160077155A (ko) | 인간 암을 치료하기 위한 특이적 항-ｃｄ38 항체 | |
| KR20130010123A (ko) | ＴＮＦ-α 결합 단백질 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| KR20130101123A (ko) | ＴＮＦ-α 결합 단백질 | |
| JPWO2019175226A5 (he) | ||
| JPWO2019175220A5 (he) | ||
| JPWO2019175217A5 (he) | ||
| JPWO2019175216A5 (he) | ||
| JPWO2019175222A5 (he) | ||
| JPWO2019175224A5 (he) | ||
| US20220372161A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| CN111763259A (zh) | 抗cd40抗体及其用途 | |
| WO2020068774A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| JPWO2020089473A5 (he) | ||
| JPWO2020089474A5 (he) | ||
| RU2021115563A (ru) | Новые молекулы агонистических анти-tnfr2 антител | |
| CN111848794A (zh) | 一种分离的lag-3结合蛋白及其应用 | |
| TWI839395B (zh) | 靶向cd137的抗體及其使用方法 |